Clinical trial trends over the last 5 years among the BRICS (Brazil, Russia, India, China, and South Africa) nations

Q2 Medicine

Perspectives in Clinical Research Pub Date : 2023-10-27 DOI:10.4103/picr.picr_179_23

Kaviya Manoharan, Juanna Jinson, Kalaivani Ramesh, Melvin George

{"title":"Clinical trial trends over the last 5 years among the BRICS (Brazil, Russia, India, China, and South Africa) nations","authors":"Kaviya Manoharan, Juanna Jinson, Kalaivani Ramesh, Melvin George","doi":"10.4103/picr.picr_179_23","DOIUrl":null,"url":null,"abstract":"Abstract Purpose: Although the Americas and Europe have historically dominated the global research landscape, emerging economies – Brazil, Russia, India, China, and South Africa (BRICS) have significantly increased their contributions in recent years. This article studies clinical trial trends in the BRICS nations between 2018 and 2022 and compares it with trends in the G7 nations (comprising Canada, France, Germany, Italy, Japan, the UK, the USA, and the European Union). This will help stakeholders in planning drug development strategies. Materials and Methods: Data were collected from the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and the World Bank database. An electronic search was done for the total number of trials registered between January 1, 2018, and March 15, 2023. Information was analyzed based on the year of registration, therapeutic area, type of intervention, sponsorship, and type of special population. The trial density indices (TDIs) were calculated based on population (Xi) and gross domestic product (GDP) (Yi) using author-derived formulae. Results: Altogether 2, 77, 536 trials from the BRICS and G7 were registered. China and the US had the most trials among the BRICS and G7, respectively. Between 2018 and 2022, the gap between the BRICS and G7 steadily reduced. The most common indication for clinical trials among the BRICS was cancer. Based on population, the TDI was the highest in China and the lowest in Russia. In proportion to the GDP, the TDI was maximum in Russia and minimum in India. Conclusion: There is a remarkable reduction in the gap in clinical trial trends between the BRICS and G7 nations. Among the BRICS, India and China are at the forefront in drug development. There is scope for improvement in trial density based on India’s population and GDP. Stakeholders are likely to utilize the strengths of the BRICS as an attractive destination for investment in this area.","PeriodicalId":20015,"journal":{"name":"Perspectives in Clinical Research","volume":"18 4","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives in Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/picr.picr_179_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Purpose: Although the Americas and Europe have historically dominated the global research landscape, emerging economies – Brazil, Russia, India, China, and South Africa (BRICS) have significantly increased their contributions in recent years. This article studies clinical trial trends in the BRICS nations between 2018 and 2022 and compares it with trends in the G7 nations (comprising Canada, France, Germany, Italy, Japan, the UK, the USA, and the European Union). This will help stakeholders in planning drug development strategies. Materials and Methods: Data were collected from the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and the World Bank database. An electronic search was done for the total number of trials registered between January 1, 2018, and March 15, 2023. Information was analyzed based on the year of registration, therapeutic area, type of intervention, sponsorship, and type of special population. The trial density indices (TDIs) were calculated based on population (Xi) and gross domestic product (GDP) (Yi) using author-derived formulae. Results: Altogether 2, 77, 536 trials from the BRICS and G7 were registered. China and the US had the most trials among the BRICS and G7, respectively. Between 2018 and 2022, the gap between the BRICS and G7 steadily reduced. The most common indication for clinical trials among the BRICS was cancer. Based on population, the TDI was the highest in China and the lowest in Russia. In proportion to the GDP, the TDI was maximum in Russia and minimum in India. Conclusion: There is a remarkable reduction in the gap in clinical trial trends between the BRICS and G7 nations. Among the BRICS, India and China are at the forefront in drug development. There is scope for improvement in trial density based on India’s population and GDP. Stakeholders are likely to utilize the strengths of the BRICS as an attractive destination for investment in this area.

查看原文本刊更多论文

金砖国家(巴西、俄罗斯、印度、中国和南非)过去5年的临床试验趋势

摘要目的:尽管美洲和欧洲在历史上一直主导着全球研究格局，但近年来，新兴经济体——巴西、俄罗斯、印度、中国和南非(金砖国家)的贡献显著增加。本文研究了2018年至2022年金砖国家的临床试验趋势，并将其与G7国家(包括加拿大、法国、德国、意大利、日本、英国、美国和欧盟)的趋势进行了比较。这将有助于利益攸关方规划药物开发战略。材料和方法:数据收集自世界卫生组织国际临床试验注册平台(WHO ICTRP)和世界银行数据库。对2018年1月1日至2023年3月15日期间注册的试验总数进行了电子检索。根据注册年份、治疗区域、干预类型、赞助和特殊人群类型对信息进行分析。结果:共有来自金砖国家和七国集团的277,536项试验注册。中国和美国分别是金砖国家和七国集团中审判次数最多的国家。2018年至2022年，金砖国家与七国集团的差距稳步缩小。在金砖国家中，临床试验最常见的适应症是癌症。按人口计算，中国的TDI最高，俄罗斯最低。TDI与GDP的比例，俄罗斯最大，印度最小。结论:金砖国家和G7国家在临床试验趋势上的差距显著缩小。在金砖国家中，印度和中国在药物研发方面走在前列。根据印度的人口和GDP，试验密度还有改进的余地。利益攸关方可能会利用金砖国家的优势，将其作为该领域有吸引力的投资目的地。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Perspectives in Clinical Research Medicine-Medicine (all)

CiteScore

2.90

自引率

0.00%

发文量

审稿时长

36 weeks

期刊介绍： This peer review quarterly journal is positioned to build a learning clinical research community in India. This scientific journal will have a broad coverage of topics across clinical research disciplines including clinical research methodology, research ethics, clinical data management, training, data management, biostatistics, regulatory and will include original articles, reviews, news and views, perspectives, and other interesting sections. PICR will offer all clinical research stakeholders in India – academicians, ethics committees, regulators, and industry professionals -a forum for exchange of ideas, information and opinions.